SARS-CoV-2 reinfection and COVID-19 severity

SARS-CoV-2 reinfection rate is low. The relative severity of the first and second episodes of infection remains poorly studied. In this study, we aimed at assessing the frequency of SARS-CoV-2 reinfections and comparing the severity of the first and second episodes of infection. We retrospectively i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Emerging microbes & infections 2022-12, Vol.11 (1), p.894-901
Hauptverfasser: Nguyen, Nhu Ngoc, Houhamdi, Linda, Hoang, Van Thuan, Delerce, Jeremy, Delorme, Léa, Colson, Philippe, Brouqui, Philippe, Fournier, Pierre-Edouard, Raoult, Didier, Gautret, Philippe
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 901
container_issue 1
container_start_page 894
container_title Emerging microbes & infections
container_volume 11
creator Nguyen, Nhu Ngoc
Houhamdi, Linda
Hoang, Van Thuan
Delerce, Jeremy
Delorme, Léa
Colson, Philippe
Brouqui, Philippe
Fournier, Pierre-Edouard
Raoult, Didier
Gautret, Philippe
description SARS-CoV-2 reinfection rate is low. The relative severity of the first and second episodes of infection remains poorly studied. In this study, we aimed at assessing the frequency of SARS-CoV-2 reinfections and comparing the severity of the first and second episodes of infection. We retrospectively included patients with SARS-CoV-2 positive RT-PCR at least 90 days after clinical recovery from a COVID-19 episode and with at least one negative RT-PCR after the first infection. Whole genome sequencing and variant-specific RT-PCR were performed and clinical symptoms and severity of infection were retrospectively documented from medical files. A total of 209 COVID-19 reinfected patients were identified, accounting for 0.4% of positive cases diagnosed from 19 March 2020 to 24 August 2021. Serology was performed in 64 patients, of whom 39 (60.1%) had antibodies against SARS-CoV-2 when sampled at the early stage of their second infection. Only seven patients (3.4%) were infected twice with the same variant. We observed no differences in clinical presentation, hospitalization rate, and transfer to ICU when comparing the two episodes of infections. Our results suggest that the severity of the second episode of COVID-19 is in the same range as that of the first infection, including patients with antibodies.
doi_str_mv 10.1080/22221751.2022.2052358
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2748038532</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_cacbb5f574eb4dd78a9a1b0fb7b5cb92</doaj_id><sourcerecordid>2638023414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c596t-8c8ca6518254f1f13bf3d1c7f6838c300175e024d593e08dadf61b7ca390b4563</originalsourceid><addsrcrecordid>eNp9UttuEzEQtRCIVqWfAIrEC0hs8d3eF0QULo0UqRKFvlq-to4262JvgvL3eNm0avvAPNijmTNnxp4DwGsEzxCU8COuhgRDZxhiXA-GCZPPwPEYb8bE8wf-ETgtZQ2rCcgpoi_BEWGYUyjkMfhwOf9x2SzSVYNn2cc-eDvE1M9072aLi6vllwa1s-J3Psdh_wq8CLor_vRwn4Bf377-XJw3q4vvy8V81VjW8qGRVlrNGZKY0YACIiYQh6wIXBJpCYR1Kg8xdawlHkqnXeDICKtJCw1lnJyA5cTrkl6r2xw3Ou9V0lH9C6R8rXQeou28stoawwIT1BvqnJC61cjAYIRh1rS4cn2auG63ZuOd9f2QdfeI9HGmjzfqOu2UbCmmLawE7yeCmydl5_OVGmOQcE4kIztUse8OzXL6vfVlUJtYrO863fu0LQpXIMSkLqFC3z6BrtM29_VbFRZUwpFxnJ5NKJtTKdmH-wkQVKMU1J0U1CgFdZBCrXvz8NX3VXeLr4DPE6CuPOWN_pNy59Sg913KIevexqLI_3v8Bfbuvj8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2748038532</pqid></control><display><type>article</type><title>SARS-CoV-2 reinfection and COVID-19 severity</title><source>Taylor &amp; Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Nguyen, Nhu Ngoc ; Houhamdi, Linda ; Hoang, Van Thuan ; Delerce, Jeremy ; Delorme, Léa ; Colson, Philippe ; Brouqui, Philippe ; Fournier, Pierre-Edouard ; Raoult, Didier ; Gautret, Philippe</creator><creatorcontrib>Nguyen, Nhu Ngoc ; Houhamdi, Linda ; Hoang, Van Thuan ; Delerce, Jeremy ; Delorme, Léa ; Colson, Philippe ; Brouqui, Philippe ; Fournier, Pierre-Edouard ; Raoult, Didier ; Gautret, Philippe</creatorcontrib><description>SARS-CoV-2 reinfection rate is low. The relative severity of the first and second episodes of infection remains poorly studied. In this study, we aimed at assessing the frequency of SARS-CoV-2 reinfections and comparing the severity of the first and second episodes of infection. We retrospectively included patients with SARS-CoV-2 positive RT-PCR at least 90 days after clinical recovery from a COVID-19 episode and with at least one negative RT-PCR after the first infection. Whole genome sequencing and variant-specific RT-PCR were performed and clinical symptoms and severity of infection were retrospectively documented from medical files. A total of 209 COVID-19 reinfected patients were identified, accounting for 0.4% of positive cases diagnosed from 19 March 2020 to 24 August 2021. Serology was performed in 64 patients, of whom 39 (60.1%) had antibodies against SARS-CoV-2 when sampled at the early stage of their second infection. Only seven patients (3.4%) were infected twice with the same variant. We observed no differences in clinical presentation, hospitalization rate, and transfer to ICU when comparing the two episodes of infections. Our results suggest that the severity of the second episode of COVID-19 is in the same range as that of the first infection, including patients with antibodies.</description><identifier>ISSN: 2222-1751</identifier><identifier>EISSN: 2222-1751</identifier><identifier>DOI: 10.1080/22221751.2022.2052358</identifier><identifier>PMID: 35264078</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Bacteriology ; Cardiology and cardiovascular system ; coronavirus ; Coronaviruses ; COVID-19 ; Emerging diseases ; Human health and pathology ; Humans ; Infections ; Infectious diseases ; Life Sciences ; Microbiology and Parasitology ; Parasitology ; Reinfection ; Retrospective Studies ; SARS-CoV-2 ; SARS-CoV-2 - genetics ; Severe acute respiratory syndrome coronavirus 2 ; severity ; Virology ; Whole Genome Sequencing</subject><ispartof>Emerging microbes &amp; infections, 2022-12, Vol.11 (1), p.894-901</ispartof><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2022</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><rights>2022 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2022 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c596t-8c8ca6518254f1f13bf3d1c7f6838c300175e024d593e08dadf61b7ca390b4563</citedby><cites>FETCH-LOGICAL-c596t-8c8ca6518254f1f13bf3d1c7f6838c300175e024d593e08dadf61b7ca390b4563</cites><orcidid>0000-0002-2895-5824 ; 0000-0002-6125-2805 ; 0000-0003-1369-8615 ; 0000-0002-5910-1645 ; 0000-0001-8463-8885 ; 0000-0002-4126-9167 ; 0000-0002-0633-5974 ; 0000-0002-1664-958X ; 0000-0001-6285-0308</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942490/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942490/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,27502,27924,27925,53791,53793,59143,59144</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35264078$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://amu.hal.science/hal-03663853$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Nguyen, Nhu Ngoc</creatorcontrib><creatorcontrib>Houhamdi, Linda</creatorcontrib><creatorcontrib>Hoang, Van Thuan</creatorcontrib><creatorcontrib>Delerce, Jeremy</creatorcontrib><creatorcontrib>Delorme, Léa</creatorcontrib><creatorcontrib>Colson, Philippe</creatorcontrib><creatorcontrib>Brouqui, Philippe</creatorcontrib><creatorcontrib>Fournier, Pierre-Edouard</creatorcontrib><creatorcontrib>Raoult, Didier</creatorcontrib><creatorcontrib>Gautret, Philippe</creatorcontrib><title>SARS-CoV-2 reinfection and COVID-19 severity</title><title>Emerging microbes &amp; infections</title><addtitle>Emerg Microbes Infect</addtitle><description>SARS-CoV-2 reinfection rate is low. The relative severity of the first and second episodes of infection remains poorly studied. In this study, we aimed at assessing the frequency of SARS-CoV-2 reinfections and comparing the severity of the first and second episodes of infection. We retrospectively included patients with SARS-CoV-2 positive RT-PCR at least 90 days after clinical recovery from a COVID-19 episode and with at least one negative RT-PCR after the first infection. Whole genome sequencing and variant-specific RT-PCR were performed and clinical symptoms and severity of infection were retrospectively documented from medical files. A total of 209 COVID-19 reinfected patients were identified, accounting for 0.4% of positive cases diagnosed from 19 March 2020 to 24 August 2021. Serology was performed in 64 patients, of whom 39 (60.1%) had antibodies against SARS-CoV-2 when sampled at the early stage of their second infection. Only seven patients (3.4%) were infected twice with the same variant. We observed no differences in clinical presentation, hospitalization rate, and transfer to ICU when comparing the two episodes of infections. Our results suggest that the severity of the second episode of COVID-19 is in the same range as that of the first infection, including patients with antibodies.</description><subject>Bacteriology</subject><subject>Cardiology and cardiovascular system</subject><subject>coronavirus</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Emerging diseases</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Life Sciences</subject><subject>Microbiology and Parasitology</subject><subject>Parasitology</subject><subject>Reinfection</subject><subject>Retrospective Studies</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 - genetics</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>severity</subject><subject>Virology</subject><subject>Whole Genome Sequencing</subject><issn>2222-1751</issn><issn>2222-1751</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNp9UttuEzEQtRCIVqWfAIrEC0hs8d3eF0QULo0UqRKFvlq-to4262JvgvL3eNm0avvAPNijmTNnxp4DwGsEzxCU8COuhgRDZxhiXA-GCZPPwPEYb8bE8wf-ETgtZQ2rCcgpoi_BEWGYUyjkMfhwOf9x2SzSVYNn2cc-eDvE1M9072aLi6vllwa1s-J3Psdh_wq8CLor_vRwn4Bf377-XJw3q4vvy8V81VjW8qGRVlrNGZKY0YACIiYQh6wIXBJpCYR1Kg8xdawlHkqnXeDICKtJCw1lnJyA5cTrkl6r2xw3Ou9V0lH9C6R8rXQeou28stoawwIT1BvqnJC61cjAYIRh1rS4cn2auG63ZuOd9f2QdfeI9HGmjzfqOu2UbCmmLawE7yeCmydl5_OVGmOQcE4kIztUse8OzXL6vfVlUJtYrO863fu0LQpXIMSkLqFC3z6BrtM29_VbFRZUwpFxnJ5NKJtTKdmH-wkQVKMU1J0U1CgFdZBCrXvz8NX3VXeLr4DPE6CuPOWN_pNy59Sg913KIevexqLI_3v8Bfbuvj8</recordid><startdate>20221231</startdate><enddate>20221231</enddate><creator>Nguyen, Nhu Ngoc</creator><creator>Houhamdi, Linda</creator><creator>Hoang, Van Thuan</creator><creator>Delerce, Jeremy</creator><creator>Delorme, Léa</creator><creator>Colson, Philippe</creator><creator>Brouqui, Philippe</creator><creator>Fournier, Pierre-Edouard</creator><creator>Raoult, Didier</creator><creator>Gautret, Philippe</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><general>Earliest : Springer-Nature ; Latest : Taylor &amp; Francis</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2895-5824</orcidid><orcidid>https://orcid.org/0000-0002-6125-2805</orcidid><orcidid>https://orcid.org/0000-0003-1369-8615</orcidid><orcidid>https://orcid.org/0000-0002-5910-1645</orcidid><orcidid>https://orcid.org/0000-0001-8463-8885</orcidid><orcidid>https://orcid.org/0000-0002-4126-9167</orcidid><orcidid>https://orcid.org/0000-0002-0633-5974</orcidid><orcidid>https://orcid.org/0000-0002-1664-958X</orcidid><orcidid>https://orcid.org/0000-0001-6285-0308</orcidid></search><sort><creationdate>20221231</creationdate><title>SARS-CoV-2 reinfection and COVID-19 severity</title><author>Nguyen, Nhu Ngoc ; Houhamdi, Linda ; Hoang, Van Thuan ; Delerce, Jeremy ; Delorme, Léa ; Colson, Philippe ; Brouqui, Philippe ; Fournier, Pierre-Edouard ; Raoult, Didier ; Gautret, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c596t-8c8ca6518254f1f13bf3d1c7f6838c300175e024d593e08dadf61b7ca390b4563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Bacteriology</topic><topic>Cardiology and cardiovascular system</topic><topic>coronavirus</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Emerging diseases</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Life Sciences</topic><topic>Microbiology and Parasitology</topic><topic>Parasitology</topic><topic>Reinfection</topic><topic>Retrospective Studies</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 - genetics</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>severity</topic><topic>Virology</topic><topic>Whole Genome Sequencing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguyen, Nhu Ngoc</creatorcontrib><creatorcontrib>Houhamdi, Linda</creatorcontrib><creatorcontrib>Hoang, Van Thuan</creatorcontrib><creatorcontrib>Delerce, Jeremy</creatorcontrib><creatorcontrib>Delorme, Léa</creatorcontrib><creatorcontrib>Colson, Philippe</creatorcontrib><creatorcontrib>Brouqui, Philippe</creatorcontrib><creatorcontrib>Fournier, Pierre-Edouard</creatorcontrib><creatorcontrib>Raoult, Didier</creatorcontrib><creatorcontrib>Gautret, Philippe</creatorcontrib><collection>Taylor &amp; Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Emerging microbes &amp; infections</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguyen, Nhu Ngoc</au><au>Houhamdi, Linda</au><au>Hoang, Van Thuan</au><au>Delerce, Jeremy</au><au>Delorme, Léa</au><au>Colson, Philippe</au><au>Brouqui, Philippe</au><au>Fournier, Pierre-Edouard</au><au>Raoult, Didier</au><au>Gautret, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SARS-CoV-2 reinfection and COVID-19 severity</atitle><jtitle>Emerging microbes &amp; infections</jtitle><addtitle>Emerg Microbes Infect</addtitle><date>2022-12-31</date><risdate>2022</risdate><volume>11</volume><issue>1</issue><spage>894</spage><epage>901</epage><pages>894-901</pages><issn>2222-1751</issn><eissn>2222-1751</eissn><abstract>SARS-CoV-2 reinfection rate is low. The relative severity of the first and second episodes of infection remains poorly studied. In this study, we aimed at assessing the frequency of SARS-CoV-2 reinfections and comparing the severity of the first and second episodes of infection. We retrospectively included patients with SARS-CoV-2 positive RT-PCR at least 90 days after clinical recovery from a COVID-19 episode and with at least one negative RT-PCR after the first infection. Whole genome sequencing and variant-specific RT-PCR were performed and clinical symptoms and severity of infection were retrospectively documented from medical files. A total of 209 COVID-19 reinfected patients were identified, accounting for 0.4% of positive cases diagnosed from 19 March 2020 to 24 August 2021. Serology was performed in 64 patients, of whom 39 (60.1%) had antibodies against SARS-CoV-2 when sampled at the early stage of their second infection. Only seven patients (3.4%) were infected twice with the same variant. We observed no differences in clinical presentation, hospitalization rate, and transfer to ICU when comparing the two episodes of infections. Our results suggest that the severity of the second episode of COVID-19 is in the same range as that of the first infection, including patients with antibodies.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>35264078</pmid><doi>10.1080/22221751.2022.2052358</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-2895-5824</orcidid><orcidid>https://orcid.org/0000-0002-6125-2805</orcidid><orcidid>https://orcid.org/0000-0003-1369-8615</orcidid><orcidid>https://orcid.org/0000-0002-5910-1645</orcidid><orcidid>https://orcid.org/0000-0001-8463-8885</orcidid><orcidid>https://orcid.org/0000-0002-4126-9167</orcidid><orcidid>https://orcid.org/0000-0002-0633-5974</orcidid><orcidid>https://orcid.org/0000-0002-1664-958X</orcidid><orcidid>https://orcid.org/0000-0001-6285-0308</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2222-1751
ispartof Emerging microbes & infections, 2022-12, Vol.11 (1), p.894-901
issn 2222-1751
2222-1751
language eng
recordid cdi_proquest_journals_2748038532
source Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Bacteriology
Cardiology and cardiovascular system
coronavirus
Coronaviruses
COVID-19
Emerging diseases
Human health and pathology
Humans
Infections
Infectious diseases
Life Sciences
Microbiology and Parasitology
Parasitology
Reinfection
Retrospective Studies
SARS-CoV-2
SARS-CoV-2 - genetics
Severe acute respiratory syndrome coronavirus 2
severity
Virology
Whole Genome Sequencing
title SARS-CoV-2 reinfection and COVID-19 severity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T00%3A42%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SARS-CoV-2%20reinfection%20and%20COVID-19%20severity&rft.jtitle=Emerging%20microbes%20&%20infections&rft.au=Nguyen,%20Nhu%20Ngoc&rft.date=2022-12-31&rft.volume=11&rft.issue=1&rft.spage=894&rft.epage=901&rft.pages=894-901&rft.issn=2222-1751&rft.eissn=2222-1751&rft_id=info:doi/10.1080/22221751.2022.2052358&rft_dat=%3Cproquest_cross%3E2638023414%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2748038532&rft_id=info:pmid/35264078&rft_doaj_id=oai_doaj_org_article_cacbb5f574eb4dd78a9a1b0fb7b5cb92&rfr_iscdi=true